Related Experiment Video
Updated: Sep 17, 2025
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.2K
Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma
John P Micha1, Randy D Bohart2, Joshua P Gorman3
1Women's Cancer Research Foundation, Laguna Beach, CA, U.S.A.
Anticancer Research
|June 27, 2025
Summary
Immunotherapy combined with chemotherapy improves survival for advanced endometrial cancer. Dostarlimab shows promising survival data compared to other immunotherapies in mismatch repair deficient and proficient patients.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Immunotherapy
Background:
- Early-stage endometrial cancer has high survival rates with standard treatments.
- Advanced or recurrent endometrial cancer historically has poorer outcomes.
- Immunotherapy, particularly in combination with chemotherapy, offers improved survival, especially for mismatch repair deficient (dMMR) patients.
Purpose of the Study:
- To review the efficacy of immunotherapy treatments for advanced or recurrent endometrial cancer.
- To compare the survival outcomes of dostarlimab, pembrolizumab, and durvalumab in combination with chemotherapy.
Main Methods:
- Extensive PubMed search on endometrial cancer and immunotherapy.
- Analysis of progression-free survival (PFS) and overall survival (OS) data.
- Comparison of treatment outcomes across different immunotherapy agents.
Main Results:
- Dostarlimab combined with chemotherapy demonstrated a 61% 2-year PFS.
- Dostarlimab showed extended follow-up data (median OS not reached) compared to pembrolizumab and durvalumab.
- While associated with disease progression risks in both dMMR (70%) and pMMR (46%) patients, dostarlimab exhibited superior survival data.
Conclusions:
- Dostarlimab, pembrolizumab, and durvalumab with chemotherapy benefit advanced or recurrent endometrial cancer.
- Dostarlimab presents superior survival outcomes compared to pembrolizumab and durvalumab in this patient population.
Keywords:
Endometrial cancerchemotherapyimmunotherapymismatch repair statusoutcomesreviewtolerabilityMore Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.7K
Related Concept Videos
01:27Tumor Immunotherapy
667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
01:30Cancer Vaccines
517
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
517
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:17The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K